BioCryst Pharmaceuticals (NASDAQ:BCRX) Given Buy Rating at HC Wainwright

BioCryst Pharmaceuticals (NASDAQ:BCRX)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a report released on Tuesday,Benzinga reports. They presently have a $30.00 price objective on the biotechnology company’s stock. HC Wainwright’s price target would indicate a potential upside of 261.88% from the company’s current price.

Other analysts have also recently issued research reports about the company. Royal Bank of Canada reiterated an “outperform” rating and set a $10.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. Needham & Company LLC increased their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a report on Monday, January 13th. Barclays boosted their target price on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th. Evercore ISI upped their target price on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a research report on Monday, January 13th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $18.00 price target on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, BioCryst Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $15.50.

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ BCRX opened at $8.29 on Tuesday. The stock has a market cap of $1.72 billion, a PE ratio of -13.59 and a beta of 1.75. BioCryst Pharmaceuticals has a 1 year low of $4.03 and a 1 year high of $9.50. The firm has a fifty day moving average price of $8.03 and a 200-day moving average price of $7.84.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The company had revenue of $131.50 million for the quarter, compared to the consensus estimate of $130.05 million. The business’s revenue for the quarter was up 40.8% compared to the same quarter last year. During the same period in the prior year, the company earned $0.28 earnings per share. On average, research analysts expect that BioCryst Pharmaceuticals will post -0.36 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its position in BioCryst Pharmaceuticals by 7.8% during the fourth quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company’s stock valued at $164,616,000 after purchasing an additional 1,583,826 shares during the last quarter. Eversept Partners LP raised its position in shares of BioCryst Pharmaceuticals by 269.9% during the 4th quarter. Eversept Partners LP now owns 1,980,312 shares of the biotechnology company’s stock valued at $14,892,000 after buying an additional 1,444,907 shares in the last quarter. Hillsdale Investment Management Inc. lifted its holdings in shares of BioCryst Pharmaceuticals by 65,213.3% in the 4th quarter. Hillsdale Investment Management Inc. now owns 542,100 shares of the biotechnology company’s stock valued at $4,077,000 after acquiring an additional 541,270 shares during the last quarter. Balyasny Asset Management L.P. purchased a new position in BioCryst Pharmaceuticals in the fourth quarter worth about $3,983,000. Finally, Norges Bank bought a new stake in BioCryst Pharmaceuticals during the fourth quarter worth approximately $3,947,000. 85.88% of the stock is owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.